Andrew Ko, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1825 4th Street, #L4101
San Francisco CA 94107
Phone415-353-7286
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown University, Providence, RISc.B.05/1991Applied Mathematics and Biology
    Johns Hopkins School of Medicine, Baltimore, MDM.D.05/1995Medicine
    Beth Israel/Harvard Medical School, Boston, MA06/1998Internal Medicine (internship and residency)
    Stanford University, Palo Alto, CA06/2001Medical oncology (fellowship)
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer
    NIH R21CA149939Sep 19, 2011 - Aug 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024 Mar 13; 10(1):8. Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. PMID: 38475923; PMCID: PMC10935935.
      View in: PubMed   Mentions:
    2. A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer. Invest New Drugs. 2024 Mar 05. Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY. PMID: 38441850.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer. Cancer Res Commun. 2024 Jan 25; 4(1):200-212. Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen B, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko A, Fong L, Keenan BP. PMID: 38181044; PMCID: PMC10809910.
      View in: PubMed   Mentions: Translation:Humans
    4. Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer. J Clin Oncol. 2023 Dec 20; 41(36):5479-5480. O'Reilly EM, Ko AH, Friedberg JW. PMID: 38100990; PMCID: PMC10730035.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Hyperpolarized 13 C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma. J Magn Reson Imaging. 2023 Dec 02. Gordon JW, Chen HY, Nickles T, Lee PM, Bok R, Ohliger MA, Okamoto K, Ko AH, Larson PEZ, Wang ZJ. PMID: 38041836.
      View in: PubMed   Mentions:    Fields:    
    6. Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer. J Clin Oncol. 2023 10 20; 41(30):4711-4712. Ko AH. PMID: 37847994.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Interindividual variation in human cortical cell type abundance and expression. Science. 2023 10 13; 382(6667):eadf2359. Johansen N, Somasundaram S, Travaglini KJ, Yanny AM, Shumyatcher M, Casper T, Cobbs C, Dee N, Ellenbogen R, Ferreira M, Goldy J, Guzman J, Gwinn R, Hirschstein D, Jorstad NL, Keene CD, Ko A, Levi BP, Ojemann JG, Pham T, Shapovalova N, Silbergeld D, Sulc J, Torkelson A, Tung H, Smith K, Lein ES, Bakken TE, Hodge RD, Miller JA. PMID: 37824649.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity. Cancers (Basel). 2023 Jul 18; 15(14). Walker EJ, Ko AH. PMID: 37509318; PMCID: PMC10377699.
      View in: PubMed   Mentions:
    9. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 07; 21(7):753-782. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. PMID: 37433437.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    10. Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2023 06 20; 41(18):3275-3276. Ko AH. PMID: 37315388.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023 06 02; 28(6):553-e472. Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. PMID: 36940261; PMCID: PMC10243783.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 04 10; 41(11):2007-2019. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. PMID: 36521097; PMCID: PMC10082313.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    13. Precision Medicine and Immunotherapy in GI Cancers. J Clin Oncol. 2022 08 20; 40(24):2659-2661. O'Reilly EM, Ko AH. PMID: 35839433.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Pancreas. 2022 07 01; 51(6):628-633. Munigala S, Gardner TB, O'Reilly EM, Fernández-Del Castillo C, Ko AH, Pleskow D, Vollmer CM, Searle NA, Bakelman D, Holt JM, Gelrud A. PMID: 36206469.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022 06; 28(6):1167-1177. Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. PMID: 35662283; PMCID: PMC9205784.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    16. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas. 2022 04 01; 51(4):302-304. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. PMID: 35695740.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    17. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. Am J Clin Oncol. 2022 01 01; 45(1):22-27. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. PMID: 34864778.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 11; 26(11):e1982-e1991. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. PMID: 34506673; PMCID: PMC8571767.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    19. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Immunotherapy. 2021 10; 13(15):1249-1254. Tsang ES, Walker EJ, Carnevale J, Fisher GA, Ko AH. PMID: 34338034.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. The jaw-dropping costs of oral cavity cancer malpractice. Head Neck. 2021 10; 43(10):2869-2875. Wong A, Zhu D, Tong JY, Ko A, Tham T, Kraus D. PMID: 34050580.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators. PMID: 33789008.
      View in: PubMed   Mentions: 431     Fields:    Translation:HumansCTClinical Trials
    22. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 04 01; 19(4):439-457. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. PMID: 33845462.
      View in: PubMed   Mentions: 254     Fields:    Translation:Humans
    23. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 01; 22(1):118-131. O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH. PMID: 33387490.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    24. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1571-1580. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. PMID: 32880601; PMCID: PMC7489405.
      View in: PubMed   Mentions: 361     Fields:    Translation:HumansCTClinical Trials
    25. Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. J Gastrointest Oncol. 2020 Oct; 11(5):952-963. Hoang T, Dayyani F, Alfaro A, Huynh J, Ji J, Ko AH, Cho M, Hiyama D. PMID: 33209490; PMCID: PMC7657833.
      View in: PubMed   Mentions:
    26. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 11 04; 28(11):2367-2378. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. PMID: 32730744; PMCID: PMC7647666.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    27. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clin Cancer Res. 2020 09 15; 26(18):4756-4766. Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, Giannakakou P, Lenz HJ. PMID: 32641434; PMCID: PMC8209413.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    28. Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature. Anticancer Res. 2020 Jul; 40(7):3995-4000. Burns ST, Damon L, Akagi N, Laszik Z, Ko AH. PMID: 32620643.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020 09; 215(3):610-616. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. PMID: 32755156.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    30. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 10 01; 26(19):5129-5139. Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. PMID: 32591464; PMCID: PMC7541669.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    31. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. Oncologist. 2020 09; 25(9):772-779. Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. PMID: 32390297; PMCID: PMC7485368.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87. Ann Oncol. 2020 08; 31(8):1094. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. PMID: 32507672.
      View in: PubMed   Mentions: 1     Fields:    
    33. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3578-3588. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. PMID: 32273276; PMCID: PMC7727397.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    34. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020 07; 25(7):564-571. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. PMID: 32031306; PMCID: PMC7356671.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 01; 31(1):79-87. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. PMID: 31912800.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    36. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. PMID: 31634155.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032; PMCID: PMC6650370.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    38. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. PMID: 31086963; PMCID: PMC6695305.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    39. Adjuvant Therapy for Ampullary Cancer. JAMA Surg. 2019 08 01; 154(8):715. Ko AH, Nakakura EK. PMID: 31141140.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 08; 48(7):927-930. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. PMID: 31268983.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    41. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. PMID: 31126960; PMCID: PMC7376746.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    42. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia. 2019 06; 60(6):1171-1183. Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, Matias CM, Sperling MR, Buckley R, Ko A, Ojemann JG, Miller JW, Youngerman B, Sheth SA, McKhann GM, Laxton AW, Couture DE, Popli GS, Smith A, Mehta AD, Ho AL, Halpern CH, Englot DJ, Neimat JS, Konrad PE, Neal E, Vale FL, Holloway KL, Air EL, Schwalb J, Dawant BM, D'Haese PF. PMID: 31112302; PMCID: PMC6551254.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    43. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 04; 18(2):241-251. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. PMID: 30267352.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. PMID: 30865919.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    45. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 03; 43(3):334-340. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. PMID: 30211728.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    46. Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. Pancreas. 2018 Nov/Dec; 47(10):1256-1261. Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A. PMID: 30286013; PMCID: PMC7605364.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    47. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr. 2018 Oct; 7(5):406-408. Ko AH. PMID: 30498720; PMCID: PMC6230837.
      View in: PubMed   Mentions:
    48. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. PMID: 30063366.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    49. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. PMID: 29543932; PMCID: PMC5885175.
      View in: PubMed   Mentions: 811     Fields:    Translation:HumansCTClinical Trials
    50. Shifting the treatment model for resectable pancreatic cancer. Lancet Gastroenterol Hepatol. 2018 06; 3(6):375-376. Ko AH. PMID: 29625842.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. PMID: 29380678.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    52. Clinical Management: Metastatic Disease. Cancer J. 2017 Nov/Dec; 23(6):355-361. Ko AH. PMID: 29189332.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 12; 22(12):1427-e129. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. PMID: 28935773; PMCID: PMC5728028.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    54. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. PMID: 28784865.
      View in: PubMed   Mentions: 314     Fields:    Translation:Humans
    55. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade. Anticancer Res. 2017 07; 37(7):3679-3684. Greene C, Nakakura EK, Ko AH. PMID: 28668860.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89. Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. PMID: 28592615; PMCID: PMC5599193.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    57. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chin Clin Oncol. 2017 Jun; 6(3):29. Cinar P, Ko AH. PMID: 28705006.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. J Gastrointest Cancer. 2017 Mar; 48(1):94-99. Kim SS, Kim GE, Ko AH. PMID: 26961789.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2016 12; 39(6):614-618. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. PMID: 25068471; PMCID: PMC4305484.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    60. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110; PMCID: PMC5177572.
      View in: PubMed   Mentions: 10  
    61. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    62. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. J Oncol Pract. 2016 09; 12(9):808-10. Ko AH. PMID: 27621334.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. PMID: 27569043.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    64. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. PMID: 27444658.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    65. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Med Mycol Case Rep. 2016 Sep; 13:1-4. Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. PMID: 27656356; PMCID: PMC5021765.
      View in: PubMed   Mentions: 3  
    66. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016 Sep 01; 22(17):4283-90. Wang VE, Grandis JR, Ko AH. PMID: 27370606.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    67. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet. 2016 Jul 16; 388(10041):214-5. Ko AH. PMID: 27265348.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 08 01; 34(22):2654-68. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. PMID: 27247216.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    69. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016; 11:1225-35. Ko AH. PMID: 27099488; PMCID: PMC4821390.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    70. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016 06; 34(3):319-28. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. PMID: 26994014.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    71. Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope? JAMA Oncol. 2016 Mar; 2(3):380-1. Ko AH. PMID: 26658827.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    72. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. PMID: 26390428; PMCID: PMC5908466.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCellsCTClinical Trials
    73. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    74. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr; 27(4):654-60. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. PMID: 26802160; PMCID: PMC4803454.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    75. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. 2016 Feb; 12(4):453-64. Carnevale J, Ko AH. PMID: 26685802.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    76. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290; PMCID: PMC4703532.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCellsCTClinical Trials
    77. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    78. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59. Pollom EL, Koong AC, Ko AH. PMID: 26226908.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 01; 33(16):1779-86. Ko AH. PMID: 25918299.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    80. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015 Apr 15; 121(8):1287-94. Walker EJ, Ko AH, Holly EA, Bracci PM. PMID: 25649483; PMCID: PMC4393339.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    81. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. PMID: 25993177; PMCID: PMC4964785.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95. Walker EJ, Simko JP, Nakakura EK, Ko AH. PMID: 25436138; PMCID: PMC4226816.
      View in: PubMed   Mentions: 6  
    83. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015 Mar 15; 136(6):E646-53. Walker EJ, Ko AH, Holly EA, Bracci PM. PMID: 25091126; PMCID: PMC4289450.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    84. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. PMID: 25099441.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    85. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014 Jul; 34(7):3629-34. Walker EJ, Simko JP, Ko AH. PMID: 24982379.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    86. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    87. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. PMID: 24622062; PMCID: PMC3955845.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. PMID: 24633933; PMCID: PMC4265390.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    89. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014 Mar 07; 20(9):2224-36. Walker EJ, Ko AH. PMID: 24605022; PMCID: PMC3942828.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    90. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72. Cinar P, Ko AH. PMID: 24586078.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park). 2014 Jan; 28(1):5. Ko AH. PMID: 24683713.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    93. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. PMID: 23918833; PMCID: PMC3800201.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    94. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. PMID: 23880820; PMCID: PMC3749576.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    95. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998; PMCID: PMC3690907.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    96. Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response. Cell Death Differ. 2013 Apr; 20(4):620-9. Lee MS, Seo J, Choi DY, Lee EW, Ko A, Ha NC, Yoon JB, Lee HW, Kim KP, Song J. PMID: 23238566; PMCID: PMC3595487.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    97. Two patients with primary sellar leiomyomas, a rare entity. J Clin Neurosci. 2013 Jun; 20(6):897-901. Ko A, Su DK, Born D, DeSantis A, Alan Failor R, Ferreira M. PMID: 23219820.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. Achieving the best of both worlds. J Clin Oncol. 2013 Jan 01; 31(1):3-4. Ko AH, Cella D. PMID: 23213099.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    99. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    100. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. PMID: 23053263.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    101. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks. PMID: 22679115; PMCID: PMC3807091.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    102. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. PMID: 22306768; PMCID: PMC3387996.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCells
    103. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. PMID: 22306705; PMCID: PMC3387999.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    104. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. PMID: 22147736.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansPHPublic Health
    105. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011 Oct 01; 29(28):3727-9. Ko AH. PMID: 21900100.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    106. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. PMID: 21629990.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    107. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. PMID: 21460848; PMCID: PMC3755490.
      View in: PubMed   Mentions: 766     Fields:    Translation:HumansAnimalsCells
    108. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011 May; 19(5):515-42. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M, OARSI FDA Osteoarthritis Biomarkers Working Group. PMID: 21396468; PMCID: PMC3568396.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    109. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. PMID: 21245436.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    110. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Sep; 8(9):1022-31. Ko AH, Crane CH. PMID: 20876542.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    111. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    112. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807; PMCID: PMC3029022.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    113. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. Ko AH, Tempero MA. PMID: 19041649.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    114. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    115. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    116. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. Kelley RK, Ko AH. PMID: 19707431; PMCID: PMC2727779.
      View in: PubMed   Mentions: 36  
    117. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    118. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. PMID: 17893568.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    119. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):354-64. Ko AH. PMID: 17674964.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    120. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007 Dec; 15(12):1348-56. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. PMID: 17631392.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    121. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control. 2007 Oct; 18(8):809-19. Ko AH, Wang F, Holly EA. PMID: 17632765.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    122. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Mov Disord. 2007 Apr 15; 22(5):640-4. Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. PMID: 17266075.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    123. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    124. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    125. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. Ko AH, Tempero MA. PMID: 16183478.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    126. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. Ko AH, Tempero MA. PMID: 16194454.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    127. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098; PMCID: PMC2361548.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    128. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. Ko AH, Bergsland EK, Lee GA. PMID: 12645810.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    129. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma. 2002 Sep; 43(9):1789-93. Ko AH, Yuen AR. PMID: 12685833.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. Ko AH, Tempero MA. PMID: 11937010.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    131. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med. 2002 Feb; 2(1):67-82. Harmon EB, Ko AH, Kim SK. PMID: 11898849.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    132. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002 Jan; 16(1):85-99. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. PMID: 11773441.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    133. Radiation after mastectomy in high-risk patients: is it necessary? Am Surg. 2001 Dec; 67(12):1209-12. Patterson S, Ko A, O'Connell TX. PMID: 11768832.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer. 1998; 77(2):181-5. Chen Z, Ko A, Yang J, Jordan VC. PMID: 9460986; PMCID: PMC2151219.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    135. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr; 22(4):671-82. Gallant JE, Ko AH. PMID: 8729207.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    136. Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. AIDS. 1995 Oct; 9(10):1195-7. Ko AH, Thomas DL, Gallant JE. PMID: 8519459.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    137. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos Alpha Omega Alpha Honor Med Soc. 1994; 57(2):11-5. Ko AH. PMID: 8022868.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Andrew's Networks
    Concepts (455)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (82)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.